Matt Abernethy insider trades: Neurocrine Biosciences (NBIX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Matt reports to the SEC
Open-market buys and sales
25 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | NBIX | ↓ Sell | 2,311 | $157.20 | $363K | Direct | Sep 15, 2026 (1d) |
| Feb 13, 2025 | NBIX | ↓ Sell | 2,558 | $116.86 | $299K | Direct | Feb 14, 2025 (1d) |
| Feb 10, 2025 | NBIX | ↓ Sell | 980 | $118.27 | $116K | Direct | Feb 12, 2025 (2d) |
| Jan 31, 2025 | NBIX | ↓ Sell | 1,283 | $152.87 | $196K | Direct | Feb 4, 2025 (4d) |
| Aug 13, 2024 | NBIX | ↓ Sell | 14,100 | $150.38 | $2.1M | Direct | Aug 15, 2024 (2d) |
| Jul 16, 2024 | NBIX | ↓ Sell | 900 | $150.04 | $135K | Direct | Jul 18, 2024 (2d) |
| May 15, 2024 | NBIX | ↓ Sell | 30,000 | $137.95 | $4.1M | Direct | May 16, 2024 (1d) |
| Feb 13, 2024 | NBIX | ↓ Sell | 1,352 | $132.85 | $180K | Direct | Feb 15, 2024 (2d) |
| Feb 8, 2024 | NBIX | ↓ Sell | 2,260 | $138.73 | $314K | Direct | Feb 8, 2024 (0d) |
| Jan 31, 2024 | NBIX | ↓ Sell | 1,283 | $140.72 | $181K | Direct | Feb 2, 2024 (2d) |
| Aug 21, 2023 | NBIX | ↓ Sell | 2,132 | $107.39 | $229K | Direct | Aug 23, 2023 (2d) |
| Feb 8, 2023 | NBIX | ↓ Sell | 28,588 | $102.61 | $2.9M | Direct | Feb 8, 2023 (0d) |
| Jan 31, 2023 | NBIX | ↓ Sell | 1,283 | $109.98 | $141K | Direct | Feb 2, 2023 (2d) |
| Feb 8, 2022 | NBIX | ↓ Sell | 4,290 | $80.53 | $345K | Direct | Feb 9, 2022 (1d) |
| Dec 1, 2021 | NBIX | ↓ Sell | 1,645 | $82.59 | $136K | Direct | Dec 3, 2021 (2d) |
| Feb 8, 2021 | NBIX | ↓ Sell | 2,910 | $116.82 | $340K | Direct | Feb 9, 2021 (1d) |
| Dec 1, 2020 | NBIX | ↓ Sell | 1,645 | $94.66 | $156K | Direct | Dec 2, 2020 (1d) |
| Nov 12, 2020 | NBIX | ↓ Sell | 2,257 | $90.74 | $205K | Direct | Nov 16, 2020 (4d) |
| Aug 5, 2020 | NBIX | ↓ Sell | 2,257 | $118.90 | $268K | Direct | Aug 7, 2020 (2d) |
| May 7, 2020 | NBIX | ↓ Sell | 15,000 | $110.21 | $1.7M | Direct | May 11, 2020 (4d) |
| Apr 28, 2020 | NBIX | ↓ Sell | 1,741 | $102.49 | $178K | Direct | Apr 30, 2020 (2d) |
| Apr 24, 2020 | NBIX | ↓ Sell | 1,934 | $99.52 | $192K | Direct | Apr 28, 2020 (4d) |
| Feb 7, 2020 | NBIX | ↓ Sell | 2,030 | $103.35 | $210K | Direct | Feb 11, 2020 (4d) |
| Dec 2, 2019 | NBIX | ↓ Sell | 1,645 | $116.33 | $191K | Direct | Dec 4, 2019 (2d) |
| Dec 3, 2018 | NBIX | ↓ Sell | 1,178 | $90.00 | $106K | Direct | Dec 6, 2018 (3d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other NBIX insiders
Open-market trades in the last 12 months
About Matt Abernethy's insider trades
Matt Abernethy is Chief Financial Officer at Neurocrine Biosciences (NBIX). Since Dec 3, 2018, Matt has reported no open-market purchases and 25 sales worth $15.3M on SEC Form 4. In the last 12 months: 1 sale ($363K).
Their filings also include grants and awards (13 filings), option exercises (9 filings), shares withheld for taxes (3 filings), gifts (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NBIX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.